PAPILLOMAVIRUS POLYPROTEIN CONSTRUCTS

Abstract: A papillomarivus polyprotein construct comprises at least two amino acid sequences fused directly or indirectly together, each of the sequences being the sequence of an early ORF protein of papillomavirus or an immunogenic variant or fragment thereof, and at least one of said sequences being other than the E6 or E7 protein sequence or an immunogenic variant or fragment thereof. Nucleic acid molecules encoding the polyprotein construct, prophylactic or therapeutic compositions comprising the polyprotein construct or the nucleic acid molecule, and methods for eliciting an immune response against papillomarivus in a host animal are also provided.

Description: "PAPILLOMA VIRUS POLYPROTEIN CONSTRUCTS" FIELD OF THE INVENTION This invention relates to polyprotein constructs and in particular polyprotein constructs comprising a plurality of papillomavirus (PV) amino acid sequences which may be used in compositions for eliciting an immune response against PV, and particularly human papillomavirus (HPV), in a host animal. BACKGROUND OF THE INVENTION Papillomaviruses induce benign hyperproliferative lesions in humans and in many animal species, some of which undergo malignant conversion. The biology of papillomavirus infection is summarised in a review by J.P. Sundberg, entitled "Papillomavirus Infections in Animals" In "Papillomaviruses and Human Disease" edited by K. Syrjanen, L. Gissmann and L.G. Koss, Springer Verlag (1987). Papillomaviruses are a family of small DNA viruses encoding up to eight early (El , E2, E3, E4, E5, E6, E7 and E8) and two late genes (LI and L2). These viruses have been classified in several distinct groups such as HPV which are differentiated into types 1 to ~ 70 depending upon DNA sequence homology. A clinicopathological grouping of HPV and the malignant potential of the lesions with which they are most frequently associated are summarised in "Papillomaviruses and Human Cancer" by H. Pfister, CRC Press, Inc. (1990). For example, HPV type 1 (HPV-1) is present in plantar warts, HPV-6 or HPV-11 are associated with condylomata acuminata (anogenital warts), and HPV-16 or HPV-18 are common in pre-malignant and malignant lesions of the cervical squamous epithelium. The immunological approach to the prevention of HPV disease requires a thorough analysis of the viral proteins against which humoral and cellular immune responses are mounted during and after infection. However, despite recent limited success (Kreider etal., 1986, /. Virol, 59, 369; Sterling et al, 1990, J. Virol., 64, 6305; Meyers et al., 1992, Science, 257, 971; Dollard et al., 1992, Genes and Development, 6, 1 131), papillomaviruses are notoriously refractory to growth in cultured cells (Teichaman and LaPorta, 1987 In "The Papovaviridae", Vol 2 edited by N.P. Salzman and P.M. Howley, p.109). As a consequence, the lack of viral reagents has delayed the analysis of the immune response to PV infection. The recent advent of recombinant expression systems in vitro has allowed the production of viral proteins encoded by both early and late genes in relatively large amounts and in a purified form (Tindie et αl., 1990, J. Cen. Virol., 71, 1347; Jarrett et αl., 1991, Virology, 184, 33; Ghim et αl., 1992, Virology, 190, 548; Stacey et αl, 1991, /. Cen. Virol., 73, 2337). These systems have, for the first time, allowed the analysis of the host immune response to these viral proteins. Interest in immune responses to the non-structural early open reading frame (ORF) proteins of HPV has centred on HPV-16 E7 because of an apparent association between serum antibodies to this protein and cervical cancer (for a review, see "Immune Response to Human Papillomaviruses and the Prospects of Human Papillomavirus-Specific Immunisation" by Tindie and Frazer In "Human Pathogenic Papillomaviruses" edited by H. zur Hausen, Current Topics in Microbiology Immunology, 186, Springer-Verlag, Berlin, 1994). The immune responses to other HPV early ORF proteins have also been investigated including HPV-16 E6 (Stacey et αl., 1992, /. Cen. Virol., 73, 2337; Bleul et αl., 1991, 7. Clin. Microbiol., 29, 1579; Dillner, 1990, Int. j. Cancer, 46, 703; and MύUer et αl., 1992, Virology, 187, 508), HPV-16 E2 (Dillner et αl., 1989 Proc.Natl. Acad. Sci.USA, 86, 3838; Dillner, 1990, supra; Lehtinen et αl., 1992, ;. Med. Virol., 37, 180; Mann et αl., 1990, Cancer Res., 50, 7815; and Jenison et αl., 1990, ;. Infect. Dis., 162, 60) and HPV-16 E4 (Kόchel et αl., 1991, Int. J. Cancer, 48, 682; Jochmus-Kudielka et αl., 1989, ;/VC/, 81, 1698; and Barber et αl., 1992, Cancer Immunol. Immυnother., 35, 33). However, comparison of these studies reveals a lack of correlation between the results of the various assays which have been used in assessing HPV early ORF protein reactivity in serum (Tindie and Frazer, 1994, supra). In addition, antibodies to other HPV early ORF proteins have not yet been sought with sufficient rigour in large enough numbers of patients to determine their utility as disease markers or as indicators of HPV protein immunogenicity following HPV infection. A problem associated with immunising animals with preparations of individual PV proteins is that most of these proteins are comparatively small and might therefore not comprise many reactive epitopes. In addition, immunodominance of particular B or T cell epitopes within a single PV protein would vary presumably between animals of different major histocompatibility (MHC) backgrounds. To this end, the efficacy of such immunogens, in respect of eliciting an immune response against PV, might be expected to differ between animals of diverse MHC background. In addition, there is surprisingly little knowledge regarding which PV proteins are expressed by infected cells at various stages of differentiation, and hence it is not possible to predict which proteins will be responsible for defining appropriate immunological targets. The present invention provides a polyprotein construct comprising a plurality of PV early ORF proteins in one fused or linked construct to improve the efficacy of immune stimulation against PV infection and to avoid the need to define specific immunological targets. SUMMARY OF THE INVENTION In one aspect, the present invention provides as an isolated product, a polyprotein construct comprising at least two amino acid sequences fused directly or indirectly together, each of said sequences being the sequence of an early open reading frame (ORF) protein of papillomavirus (PV) or an immunogenic variant or fragment thereof, and at least one of said sequences being other than the E6 or E7 protein sequence or an immunogenic variant or fragment thereof. In yet another aspect, the present invention provides a composition for eliciting a humoral and/or cellular immune response against PV in a host animal, said composition comprising an immunologically effective amount of a construct as described above, together with a pharmaceutically acceptable carrier and/or diluent. In yet another aspect, this invention provides a method for eliciting a humoral and/or cellular response against PV in a host animal, which method comprises administering to the host animal an immunologically effective amount of a polyprotein construct as described above. In a related aspect, the invention also extends to use of such a polyprotein construct in eliciting an immune response against PV in a host animal. Preferably, the host animal is a human, however the host animal may also be a non- human mammal. The present invention also extends to a nucleic acid molecule which encodes a polypeptide construct as broadly described above. Such a nucleic acid molecule may be delivered to a host animal in a nucleic acid vaccine composition with a pharmaceutically acceptable carrier and/or diluent, for expression of the encoded polyprotein construct in vivo in a host animal. Alternatively, the nucleic acid molecule may be included in a recombinant DNA molecule comprising an expression control sequence operatively linked to the nucleic acid molecule. Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers." DETAILED DESCRIPTION OF THE INVENTION The term "polyprotein construct" as used herein is used to describe a protein construct made up of individual proteins that have been joined together in a sequence whereby they retain their original relevant biological activities. The term "isolated" as used herein denotes that the polyprotein construct has undergone at least one purification or isolation step, and preferably is in a form suitable for administration to a host animal. By use of the term "immunologically effective amount" herein in the context of treatment of PV infection, it is meant that the administration of that amount to an individual PV infected host, either in a single dose or as part of a series, that is effective for treatment of PV infection. By the use of the term "immunologically effective amount" herein in the context of prevention of PV infection, it is meant that the administration of that amount to an individual host, either in a single dose or as part of a series, that is effective to delay, inhibit, treat or prevent PV infection or disease. The effective amount varies depending upon the health and physical condition of the individual to be treated, the taxonomic group of individual to be treated, the capacity of the individual's immune system to synthesise antibodies, the degree of protection desired, the formulation of the immunogen, the assessment of the medical situation, and other relevant factors. It is expected that the amount will fall in a relatively broad range that can be determined through routine trials. Preferably, the amino acid sequences in the polyprotein construct substantially correspond to the sequences of wild-type early ORF proteins of PV, including allelic or other variants thereof. Suitable variants include variants having single or multiple amino acid substitutions or additions to the wild-type sequences, and may have at least 50-60%, more preferably at least 70-80%, and most preferably at least 90%, similarity to the wild- type amino acid sequences, provided the variant is capable of eliciting an immune response against PV in a host animal. The amino acid sequences may also be immunogenic fragments of the wild-type early ORF proteins, that is fragments of the proteins which are capable of eliciting an immune response in a host animal. Suitably, the immunogenic fragment will comprise at least five, and more preferably at least ten, 5 contiguous amino acid residues of the particular protein. Such immunogenic fragments may also be recognised by PV-specific antibodies, particularly antibodies which have a protective or therapeutic effect in relation to PV infection. Preferably, the immunogenic fragment is a non-full length fragment of a wild-type amino acid sequence, which may for example comprise a deletion mutant of an early ORF protein corresponding to at least 10 50%, more preferably 60-70%, and even 80-90% of the full length wild-type amino acid sequence. The amino acid sequences in the polyprotein construct of the present invention may be selected from the group consisting of the E1, E2, E3, E4, E5 (E5a, E5b), E6, E7 and 5 E8 proteins of PV, and may be included in the construct in any desired order. By way of example, the construct may be selected from the group consisting of: (a) E6/E4 (b) E6/E5a/E4 (c) E6/E7/E4 0 (d) E6/E7/E5a/E4 (e) E6/E7/E1/E4 (f) E6/E7/E5a/E1/E4 (g) E6/E7/E5a/E1/E2/E4 (h) E6/E7/E5a/E5b/E1/E2/E4 5 (i) E2/E5b (j) E2/E1/E5b (k) E2/E5a/E5b (I) E2/E1/E5a/E5b (m) E2/E4/E5a/E5b/E6/E7/E1 0 (n) E2/E3/E4/E5/E8/E6/E7/E1. As described above, at least one of the early ORF proteins is other than the E6 or E7 proteins. Preferably one of the early ORF proteins in the construct is the E4 protein. The polyprotein constructs of this invention preferably comprise at least three, and 5 more preferably three, four or five early ORF protein sequences. In addition, two or more different polyprotein constructs based on different combinations of early ORF proteins and/or different PV genotypes may be included in a single composition for prophylactic or therapeutic use. 10 In the polyprotein constructs of this invention, the amino acid sequences may be fused or linked directly together. Alternatively, they may be linked with a linker sequence of from 1 to 50, preferably 1 to 20, and more preferably 1 to 5, amino acid residues between the separate amino acid sequences. By way of example, such a linker sequence may be an amino acid sequence encoded by the nucleotide sequence 15 comprising a restriction endonuclease site. Linker sequences as described above may also be provided before and/or after the amino acid sequences in the polyprotein constructs. The polyprotein constructs of this invention may also comprise a tag protein or 20 peptide moiety fused or otherwise coupled thereto to assist in purification of the polyprotein construct. Suitable tag moieties include, for example, (His) 6 , glutathione-S- transferase (GST) and FLAG (International Biotechnologies), with the (His) 6 tag moiety being preferred. The constructs may further comprise a component to enhance the immunogenicity of the polyprotein. The component may be an adjuvant such as 25 diphtheria or cholera toxin or E. coli heat labile toxin (LT), or a non-toxic derivative thereof such as the holotoxoid or B subunit of cholera toxin or LT. In addition, the polyprotein construct of the invention may comprise a lipid binding region to facilitate incorporation into ISCOMs. Suitable lipid binding regions are disclosed by way of example in Australian Provisional Patent Application No. PN8867/96, dated 25 March 30 1996. A preferred lipid binding region is an influenza haemagglutinin tail. The present invention also provides a nucleic acid molecule comprising a sequence of nucleotides which encodes a polyprotein construct as broadly described above. The nucleic acid molecule may be RNA or DNA, single stranded or double stranded, in linear or covalently closed circular form. It will be appreciated that the sequence of nucleotides of this aspect of the invention may be obtained from natural, synthetic or semi-synthetic sources; furthermore, this nucleotide sequence may be a naturally-occurring sequence, or it may be related by mutation, including single or multiple base substitutions, deletions, insertions and inversions, to such a naturally- occurring sequence, provided always that the nucleic acid molecule comprising such a sequence is capable of being expressed as a polyprotein construct as described herein. The nucleotide sequence may have expression control sequences positioned adjacent to it, such control sequences being derived from either a homologous or a heterologous source. Since nucleic acid molecules may be delivered directly as "naked DNA" to a host animal, (see, for example, Wolfe et al, 1990, Science 247:1465 and Fynan et al, 1993, Proc.Natl. Acad. Sci. USA, 90:11478), the present invention also includes a nucleic acid vaccine composition comprising a nucleic acid molecule as described above, together with a pharmaceutically acceptable carrier and/or diluent. Immunisation with an isolated nucleic acid molecule allows in vivo synthesis of the encoded polyprotein construct by the host animal in a manner similar to the manner in which PV proteins are expressed during infection by PV. In this aspect, the present invention also extends to a method for eliciting an immune response against PV in a host animal, which method comprises administering to the host animal an immunologically effective amount of a nucleic acid molecule as described above. The invention also extends to use of such a nucleic acid molecule in eliciting an immune response against PV in a host animal. This invention also provides a recombinant DNA molecule comprising an expression control sequence having promoter and initiator sequences, the nucleotide sequence encoding the polyprotein construct being located 3' to the promoter and initiator sequences and a terminator sequence located 3' to this sequence of nucleotides. In yet another aspect, the invention provides a recombinant DNA cloning vehicle such as a plasmid capable of expressing the polyprotein construct, as well as a host cell containing a recombinant DNA cloning vehicle and/or a recombinant DNA molecule as described above. Suitable expression control sequences and host cell/cloning vehicle combinations are well known in the art, and are described by way of example, in Sambrook et al (1989) Molecular Cloning : A Laboratory Manual, 2nd ed. Cold Spring Harbor, New York, Cold Spring Harbor Laboratory Press. Thus, the nucleotide sequence may be ligated into any suitable expression vector, which may be either a prokaryotic or eukaryotic expression vector. Preferably, the vector is a prokaryotic expression vector such as pTrcHisA or pGEX-STOP (a pGEX expression vector (Amrad/Pharmacia Biotech) which has been manipulated so as to result in truncation of the GST moiety, disclosed in Australian Provisional Patent Application No. PN8272/86, dated 26 February 1996). Whilst the host cell is preferably a prokaryotic cell, more preferably a bacterium such as £. coli, it will be understood that the host cell may alternatively be a yeast or other eukaryotic cell, or insect cells infected with baculovirus or the like. Once recombinant DNA cloning vehicles and/or host cells expressing a polyprotein construct of this invention have been identified, the expressed polypeptides synthesised by the host cells, for example, as a fusion protein, can be isolated substantially free of contaminating host cell components by techniques well known to those skilled in the art. The polyprotein construct-encoding DNA sequence is formed by linking or "fusing" sequences encoding each of the individual protein moieties. The first sequence in the polyprotein DNA construction has a promoter element and a ribosome binding site. These elements assure that transcription of the polyprotein DNA into mRNA begins at a defined site and that the signal, the ribosome binding site, needed for translation of mRNA into protein is present. Synthesis of the polyprotein is made continuous from one protein component to the next by removing or altering any initiation or binding signals and stop codons from the subsequent protein-encoding sequences. The stop codon, normally a signal for the ribosome to stop translation and to end the polypeptide, is not altered or removed from the last DNA sequence. The individual protein encoding sequences are jointed such that a proper phasing is made of the mRNA reading frames for translation of the sequence into the desired amino acids. Once a DNA sequence encoding a polyprotein construct or a "polyprotein gene" is made, it is necessary to demonstrate that the construction leads to production of a stable polyprotein construct. If the resulting protein is not stable, for example because the junctions between the proteins are vulnerable to proteolytic digestion, then the junction regions are modified. This can be done by inserting different amino acids at or near the junction or by building spacers of amino acids between the individual proteins. Linkers or spacers can also be introduced to modify the overall activity of the polyprotein. By adjusting the space between and orientation of the individual proteins it is possible to modify the total activity of the polyprotein construct. Further details of the preparation of polyprotein constructs of the present invention by recombinant DNA techniques are disclosed, by way of example, in US Patent No. 4774180, the disclosure of which is incorporated herein by reference. Preferably, the polymerase chain reaction (PCR) is used to amplify the nucleotide sequences encoding each of the individual PV early ORF proteins. The nucleotide sequences which are amplified may be full length or non full-length fragments thereof. Restriction endonuclease sites may be incorporated in the oligonucleotide primers used for PCR to furnish directional ligation of the amplification products in the same translational frame and to enable directional cloning into a suitable expression vector. The primers may encode an artificial initiator codon or a termination codon. The first nucleotide sequence has an initiator codon. This initiator codon may either be the normal wild-type initiator codon of the first sequence or may be inserted artificially at another chosen position of this sequence. Synthesis of the polyprotein construct is made continuous from one protein component to the next by removing or altering any initiation or binding signals and termination codons. The termination codon must be present in the last nucleotide sequence. This is effected normally by not altering or removing the termination codon of the last nucleotide sequence. However, this termination codon may be inserted artificially, by methods known to persons skilled in the art, by first removing the normal, wild-type termination codon of the last nucleotide sequence and inserting another, in the correct reading frame, at another position of this sequence. The polyprotein construct-encoding DNA sequence may incorporate restriction sites at the flanking ends to facilitate insertion of the DNA sequence into a suitable expression vector. The PV can be a human or an animal PV, and is preferably HPV. The HPV may be of any genotype, and may for example be selected from the group consisting of HPV- 6, HPV-11, HPV-16, HPV-18, HPV-33, HPV-35, HPV-31 and HPV-45. Preferably, the HPV is HPV-6 or HPV-11. The present invention is particularly, but not exclusively, directed to polyprotein constructs comprising early ORF proteins of the HPV-6 and HPV-11 genotypes which are causative agents of condylomata acuminata, however it will be appreciated that the invention extends to variants of the corresponding proteins in other HPV genotypes, particularly the HPV-16 and HPV-18 genotypes, and other genotypes which have oncogenic potential of a type similar to HPV-16 and HPV-18. The polyprotein constructs of the present invention may comprise early ORF proteins of a single HPV genotype, or alternatively they may comprise early ORF proteins from more than one HPV genotype. In addition, a combination of more than one polyprotein construct may be used in cases where not all early ORF proteins are represented in the one polyprotein construct, or where immune responses to more than one HPV genotype are desired. The polyprotein constructs of the present invention are provided as isolated proteins, that is they are substantially free of other PV proteins, and find particular utility for the treatment of genital warts, cervical cancer or other conditions caused by HPV in man. The polyprotein constructs can be included in pharmaceutical compositions for the treatment or prevention of diseases involving HPV as well as the other conditions discussed above. The polyprotein constructs of the invention may be used to raise antibodies and/or induce cellular immune responses, either in subjects for which protection against infection by PV is desired, i.e. as prophylactic vaccines, or to heighten the immune response to an PV infection already present, i.e. as therapeutic vaccines. They also can be injected into production species to obtain antisera. In lieu of the polyclonal antisera obtained in the production species, monoclonal antibodies may be produced using the standard methods or by more recent modifications thereof by immortalising spleen or other antibody-producing cells for injection into animals to obtain antibody-producing clones. The polyclonal or monoclonal antibodies obtained, corrected if necessary for species variations, can also be used as therapeutic agents. Direct administration of the polyprotein constructs to a host animal such as a human can confer either protective immunity against PV or, if the subject is already infected, a boost to the subject's own immune response to more effectively combat the progress of the PV induced disease. The magnitude of the prophylactic or therapeutic dose of a polyprotein constructs of this invention will, of course, vary with the group of patients (age, sex, etc.), the nature or the severity of the condition to be treated and with the particular polyprotein construct and its route of administration. In general, the weekly dose range for use lies within the range of from about 0.1 to about 5 μg per kg body weight of a mammal. Any suitable route of administration may be employed for providing a mammal, especially a human, with an effective dosage of a polyprotein construct of this invention. For example, oral, rectal, vaginal, topical, parenteral, ocular, nasal, sublingual, buccal, intravenous and the like may be employed. Dosage forms include tablets, troches, dispersions, suspensions, solutions, capsules, creams, ointments, suppositories, aerosols and the like. Said dosage forms also include injected or implanted slow releasing devices specifically designed for this purpose or other forms of implants modified to additionally act in this fashion. If the polyprotein constructs are to be administered as vaccines, they are formulated according to conventional methods for such administration to the subject to be protected. The polyprotein constructs may be delivered in accordance with this invention in ISCOMS™ (immune stimulating complexes), liposomes or encapsulated in compounds such as acrylates or poly(DL-lactide-co-glycoside) to form microspheres. They may also be incorporated into oily emulsions and delivered orally. Other adjuvants, as well as conventional pharmaceutically acceptable carriers, excipients, buffers or diluents, may also be included in vaccine compositions of this invention. Generally, a vaccine composition in accordance with the present invention will comprise an immunologically effective amount of the polyprotein construct, and optionally an adjuvant, in conjunction with one or more conventional pharmaceutically acceptable carriers and/or diluents. An extensive though not exhaustive list of adjuvants can be found in Coulter and Cox, "Advances in Adjuvant Technology and Application", in Animal Parasite Control Utilizing Biotechnology, Chapter 4, Ed. Young, W.K., CRC Press, 1992. As used herein "pharmaceutically acceptable carriers and/or diluents" include any and all solvents, dispersion media, aqueous solutions, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutical active substances is well known in the art and is described by way of example in Remington's Pharmaceutical Sciences, 18th Edition, Mack Publishing Company, Pennsylvania, U.S.A. In practical use, a polyprotein construct of this invention can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g. oral or parenteral (including intravenous and intra-arterial). In preparing the compositions for oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water glycols, oils, alcohols, flavouring agents, preservatives, colouring agents and the like in the case of oral liquid preparations, such as, for example, suspensions, elixirs and solutions; or carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations such as, for example, powders, capsules and tablets. Because of their ease of administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be sugar-coated or enteric-coated by standard techniques. In addition to the common dosage forms set out above, the polyprotein constructs of this invention may also be administered by controlled release means and/or delivery devices, including by way of example, the controlled release preparations disclosed in International Patent Specification No. PCT/AU 93/00677 (Publication No. WO 94/15636). Pharmaceutical compositions of the present invention suitable for oral or parenteral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient, as a powder or granules or as a solution or a suspension in an aqueous liquid, a non-aqueous liquid, an oil-in-water emulsion or a water-in-oil liquid emulsion. Such compositions may be prepared by any of the methods of pharmacy but all methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more necessary ingredients. In general, the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired presentation. Further features of the present invention are more fully described in the following Example(s). It is to be understood, however, that this detailed description is included solely for the purposes of exemplifying the present invention, and should not be understood in any way as a restriction on the broad description of the invention as set out above. EXAMPLES Example 1 - Amplification and cloning of early open reading frames (ORFs) of HPV6b A clone containing the entire genome of HPV6b in pBR322 (de Villiers, 1981, ;. Virol, 40:932) was used as the template for separate PCR amplifications of E6, E7, E5a, E5b, E1, E2 and E4 open reading frame (ORF) sequences. Appropriate restriction enzyme recognition sequences were included in the oligonucleotides used for amplification (Table I; 1-7) to allow sequential assembly of these amplified early gene sequences into a 'polyprotein' sequence as depicted in Figure IA. In this scheme, E6 was amplified with oligonucleotides containing a Smal site at the 5' end and HindlW, Nco\ and Xba\ sites at the 3' end. As well, E4 was amplified with oligonucleotides containing X al, Sacl, Kpnl and Spel sites 5' and a Bg/ll site 3 * . These amplified fragments were cloned as Sma\IXba\ (E6) and XbaMBglW (E4) (Figure 1B) in the vector pSP70 (Promega Corporation) which had been modified by the removal of an fcoRV/fcoRI fragment to contain a portion of the pGEM3Zf (Promega Corporation) polylinker - Hindu through fcoRI. As well, unwanted sites upstream of the Smal site were removed by cleaving with Sma\/Xho\ and insertion of a Sma\/Sal\/Xho\ linker to create the vector pSP70 (MOD). The E6/E4 cassette was able to be removed by cleavage with 5mal/βg/ll and this was then cloned for expression into the pGEX-STOP vector which produces a non-fusion protein with a C-terminal six-histidine sequence for purification purposes. Using the introduced restriction enzyme recognition sequences, other early ORF sequences were incorporated into the E6/E4 cassette cloned into pSP70 (MOD) and then the newly created cassette cloned as a Smal/Bglll fragment into pGEX-STOP. In this manner polyprotein constructs containing E6/E5a/E4, E6/E7/E4, E6/E7/E5a/E4, E6/E7/E1/E4 and E6/E7/E5a/E1/E4 were assembled. Complete DNA sequence data for the first three constructs is included and sequence data across the junctions of E1 is included for the latter two. DNA sequencing revealed the Spel site was inactivated by a single base change which occurred either during oligonucleotide synthesis, PCR or cloning. As well the tetrafusion construct of E6/E7/E5a/E4 was cloned for expression into pET23b (Novagen) by firstly subcloning the tetramer as a Smal/BglU fragment into the SmaMBamVW sites of the vector pRIT2T (AMRAD Pharmacia Biotech). The tetramer was then removed by restriction with Smal and Sa/I and cloned into the HincU/Xhol sites of the vector pET23b. A further construct containing E2 and E5b, but which could also accommodate the addition of El and E5a, was created by amplifying E2 with oligonucleotides containing a Smal site at the 5' end and Xba\, Nco\, Kpn\ and Sacl, sites at the 3' end (Table 1 ; 8) and with E5b amplified using oligonucleotides with an Xbal site 5' and Xho\, BglW sites 3' (Table 1; 9). These amplified fragments were then cloned into pSP70 (MOD) as depicted in Figure 1C. Table 1 Example 2 - Expression of different polyprotein constructs The following constructs in pGEX-STOP were expressed in E. coli strain BL21 and protein production was assayed by PAGE followed by Western blotting: i) E6/E4 ii) E6/E5a/E4 iii) E6/E7/E4 iv) E6/E7/E5a/E4 Construct (iv) in pET23b, expressed in E. coli strains BL21 (DE3)pLysS and AD494(DE3)pLysS (Novagen), was also assayed for protein production by Western blotting and also by Coomassie Blue staining for the latter strain. Cultures of 200mL were grown in Terrific broth (Tartoff and Hobbs, Focus, 9: 12, 1987) in the presence of 100 g/mL ampicillin (BL21) and 34/yg/ml cloramphenicol [BL21(DE3)pLysS] and 15 yg/mL kanamycin [AD494( DE3)pLysS]. At OD 600 ~ 1 protein expression was induced by the addition of IPTG to 0.4mM. Following induction samples were taken at 1, 2, 3, 4 and 5 hours and in some cases after overnight culture. Figure 2 shows a Western blot result for the E6/E4 construct. This was probed with a polyclonal rabbit anti-E4 antibody (MWE4 - raised to the peptide LGNEHEESNSPLATPCVWPT conjugated to ovalbumin). An immunoreactive band of ~30 kDa was present in the 4 hour-induced sample (lanes 2 & 4, arrow) which was not present in the uninduced sample (lane 3). The same ~30kDa band can also be seen in the induced sample in Figure 3, lane 3, arrow (lane 2-uninduced) while the E6/E5a/E4 trimer construct of ~ 40kDa was poorly represented after a 4 hour induction period (lane 5, arrow; uninduced sample-lane 4) using the same anti-E4 antibody. ln contrast however, a trimer construct of E6/E7/E4 (~ 41 kDa) could be easily detected after 5 hours induction using an anti-hexahistidine monoclonal antibody (Dianova) [Figure 4, lane 4, arrow; uninduced sample - lane 3]. The same trimer construct was again easily visualised after 5 hours induction using the anti-E4 antibody MWE4 (Figure 5, lane TRI, arrow; control sample - lane C) and the tetramer consisting of E6/E7/E5a/E4 (~51 kDa) could also be detected (lane TET, arrow). Although this band is weak, it must be noted that a considerable amount of high molecular weight material is also immunoreactive, indicating the tetramer is reasonably well expressed but possibly prone to aggregation. Figure 6 indicates that an anti-E6 antibody (prepared as described below) was able to detect E6/E7/E4 after 5 hours induction (lane TRI, arrow) but not E6/E7/E5a/E4 (lane TET; lane C - uninduced). However, an anti-E7 antibody (prepared as described below) was able to detect after 5 hours induction both the trimer (Figure 7, lane TRI, arrow; lane C - uninduced) and the tetramer (lane TET, arrow; lane C - uninduced), with the latter again showing indications of aggregation. A monoclonal antibody raised to an E4 peptide also recognised the trimer. The phenomenon of aggregation was clearly apparent when the E6/E7/E5a/E4 tetramer was expressed in the pET23b plasmid in BL21(DE3)pLysS (Figure 8 - a Western blot probed with MWE4). Lanes 2-5 are 1 hour, 2 hour, 3 hour and overnight uninduced samples and lanes 6-9 represent 1 hour, 2 hour, 3 hour and overnight induced samples. After 1 hour induction a band of E6/E7/E5a/E4 can clearly be seen (arrow), but with increased times of induction this seems to decrease and aggregated forms are increased. In contrast, when strain AD494(DE3)pLysS was used to express the tetramer, a substantial signal was obtained at the ~50kDa position on a Western blot of the insoluble fraction (Figure 9, arrow) following 2 hours induction, which still persisted at 3 hours. This immunoreactive band was not present in control samples and no protein was detected in the samples from the soluble fractions. Figure 10 shows the Coomassie stained profile of an identical gel, indicating that the immunoreactive bands present after 2 and 3 hours induction (Figure 9) can clearly be visualised as stained bands (arrow) which are not present in the control samples. Example 3 - DNA sequencing of polyprotein constructs Polyprotein constructs were sequenced in both directions by the dideoxy method using primers that generated overlapping sequence information. The T7 Sequencing™ Kit (Pharmacia was used to generate 35 S-labelled chain-terminated fragments which were analysed on a Sequi-Gen™ (Biorad) electrophoretic gel apparatus. The DNA and corresponding amino acid sequences for E6/E5a/E4 (CSL690.SEQ), E6/E7/E4 (CSL760.SEQ) and E6/E7/E5a/E4 (CSL673.SEQ) are shown below. (SEQ ID Nos: 19 and 20, 21 and 22, and 23 and 24, respectively). For constructs E6/E7/E1/E4 (CSL 791) and E6/E7/E5a E1/E4 (CSL 762), which were created from E6/E7/E4 and E6/E7/E5a/E4, respectively, DNA sequence analysis across the junctions of E1 with its neighbours is shown below (SEQ ID Nos. 25 and 26, 27 and 28, and 29 and 30, respectively). File : CSL690 . SEQ - 2 ^2 - Range : 1 - 11 ' Mode : Normal Codon Table : Universal E6/E5a/E4 - SEQ ID Nos, 19 (DNA) and 20 (amino acid) 9 18 27 36 45 54 5' ATG GAA AGT GCA AAT GCC TCC ACG TCT GCA ACG ACC ATA GAC CAG TTG TGC AAG Met Glu Ser Ala Asn Ala Ser Thr Ser Ala Thr Thr Ile Asp Gin Leu Cys Lys 63 72 81 90 99 108 ACG TTT AAT CTA TCT ATG CAT ACG TTG CAA ATT AAT TGT GTG TTT TGC AAG AAT Thr Phe Asn Leu Ser Met His Thr Leu Gin Ile Asn Cys Val Phe Cys Lys Asn 117 126 135 144 153 162 GCA CTG ACC ACA GCA GAG ATT TAT TCA TAT GCA TAT AAA CAC CTA AAG GTC CTG Ala Leu Thr Thr Ala Glu Ile Tyr Ser Tyr Ala Tyr Lys His Leu Lys Val Leu 171 180 189 198 207 216 TTT CGA GGC GGC TAT CCA TAT GCA GCC TGC GCG TGC TGC CTA GAA TTT CAT GGA Phe Arg Gly Gly Tyr Pro Tyr Ala Ala Cys Ala Cys Cys Leu Glu Phe His Gly 225 234 243 252 261 270 AAA ATA AAC CAA TAT AGA CAC TTT GAT TAT GCT GGA TAT GCA ACA ACA GTT GAA Lys Ile Asn Gin Tyr Arg His Phe Asp Tyr Ala Gly Tyr Ala Thr Thr Val Glu 279 288 297 306 315 324 GAA GAA ACT AAA CAA GAC ATC TTA GAC GTG CTA ATT CGG TGC TAC CTG TGT CAC Glu Glu Thr Lys Gin Asp Ile Leu Asp Val Leu Ile Arg Cys Tyr Leu Cys His 333 342 351 360 369 378 AAA CCG CTG TGT GAA GTA GAA AAG GTA AAA CAT ATA CTA ACC AAG GCG CGG TTC Lys Pro Leu Cys Glu Val Glu Lys Val Lys His Ile Leu Thr Lys Ala Arg Phe 387 396 405 414 423 432 ATA AAG CTA AAT TGT ACG TGG AAG GGT CGC TGC CTA CAC TGC TGG ACA ACA TGC Ile Lys Leu Asn Cys Thr Trp Lys Gly Arg Cys Leu His Cys Trp Thr Thr Cys 441 450 459 468 477 486 ATG GAA GAC ATG TTA CCC AAG CTT CCA TGG GAA GTG GTG CCT GTA CAA ATA GCT Met Glu Asp Met Leu Pro Lys Leu Pro Trp Glu Val Val Pro Val Gin Ile Ala 495 504 513 522 531 540 GCA GGA ACA ACC AGC ACA TTC ATA CTG CCT GTT ATA ATT GCA TTT GTT GTA TGT Ala Gly Thr Thr Ser Thr Phe Ile Leu Pro Val lie Ile Ala Phe Val Val Cys 549 558 567 576 585 594 TTT GTT AGC ATC ATA CTT ATT GTA TGG ATA TCT GAG TTT ATT GTG TAC ACA TCT Phe Val Ser Ile Ile Leu Ile Val Trp Ile Ser Glu Phe Ile Val Tyr Thr Ser 603 612 621 630 639 648 GTG CTA GTA CTA ACA CTG CTT TTA TAT TTA CTA TTG TGG CTG CTA TTA ACA ACC Val Leu Val Leu Thr Leu Leu Leu Tyr Leu Leu Leu Trp Leu Leu Leu Thr Thr 657 666 675 684 693 702 CCC TTG CAA TTT TTC CTA CTA ACT CTA CTT GTG TGT TAC TGT CCC GCA TTG TAT Pro Leu Gin Phe Phe Leu Leu Thr Leu Leu Val Cys Tyr Cys Pro Ala Leu Tyr 711 720 729 738 747 756 ATA CAC TAC TAT ATT GTT ACC ACA CAG CAA TCT AGA GAG CTC GGT ACC ACT AAT Ile His Tyr Tyr Ile Val Thr Thr Gin Gin Ser Arg Glu Leu Gly Thr Thr Asn 765 774 783 792 801 810 GGA GCA CCA AAC ATT GGG AAG TAT GTT ATG GCA GCA CAG TTA TAT GTT CTC CTG Gly Ala Pro Asn Ile Gly Lys Tyr Val Met Ala Ala Gin Leu Tyr Val Leu Leu 819 828 837 846 855 864 CAT CTG TAT CTA GCA CTA CAC AAG AAG TAT CCA TTC CTG AAT CTA CTA CAT ACA His Leu Tyr Leu Ala Leu His Lys Lys Tyr Pro Phe Leu Asn Leu Leu His Thr 873 882 891 900 909 918 CCC CCG CAC AGA CCT CCA CCC TTG TGT CCT CAA GCA CCA AGG AAG ACG CAG TGC Pro Pro His Arg Pro Pro Pro Leu Cys Pro Gin Ala Pro Arg Lys Thr Gin Cys 927 936 945 954 963 972 AAA CGC CGC CTA GGA AAC GAG CAC GAG GAG TCC AAC AGT CCC CTT GCA ACG CCT Lys Arg Arg Leu Gly Asn Glu His Glu Glu Ser Asn Ser Pro Leu Ala Thr Pro 981 990 999 1008 1017 1026 TGT GTG TGG CCC ACA TTG GAC CCG TGG ACA GTG GAA ACC ACA ACC TCA TCA CTA Cys Val Trp Pro Thr Leu Asp Pro Trp Thr Val Glu Thr Thr Thr Ser Ser Leu 1035 1044 1053 1062 1071 1080 ACA ATC ACG ACC AGC ACC AAA GAC GGA ACA ACA GTA ACA GTT CAG CTA CGC CTA Thr Ile Thr Thr Ser Thr Lys Asp Gly Thr Thr Val Thr Val Gin Leu Arg Leu 1089 1098 1107 AGA TCT CAT CAC CAT CAC CAT CAC TAA 3' Arg Ser His His His His His His *** File : CSL760.SEQ Range : 1 - 1128 Mode : Normal Codon Table : Universal E6/E7/E4 - SEQ ID Nos. 21 (DNA) and 22 (amino acid) 9 18 27 36 45 54 5' ATG GAA AGT GCA AAT GCC TCC ACG TCT GCA ACG ACC ATA GAC CAG TTG TGC AAG Met Glu Ser Ala Asn Ala Ser Thr Ser Ala Thr Thr Ile Asp Gin Leu Cys Lys 63 72 81 90 99 108 ACG TTT AAT CTA TCT ATG CAT ACG TTG CAA ATT AAT TGT GTG TTT TGC AAG AAT Thr Phe Asn Leu Ser Met His Thr Leu Gin Ile Asn Cys Val Phe Cys Lys Asn 117 126 135 144 153 162 GCA CTG ACC ACA GCA GAG ATT TAT TCA TAT GCA TAT AAA CAC CTA AAG GTC CTG Ala Leu Thr Thr Ala Glu Ile Tyr Ser Tyr Ala Tyr Lys His Leu Lys Val Leu 171 180 189 198 207 216 TTT CGA GGC GGC TAT CCA TAT GCA GCC TGC GCG TGC TGC CTA GAA TTT CAT GGA Phe Arg Gly Gly Tyr Pro Tyr Ala Ala Cys Ala Cys Cys Leu Glu Phe H s Gly 225 234 243 252 261 270 AAA ATA AAC CAA TAT AGA CAC TTT GAT TAT GCT GGA TAT GCA ACA ACA GTT GAA Lys Ile Asn Gin Tyr Arg His Phe Asp Tyr Ala Gly Tyr Ala Thr Thr Val Glu 279 288 297 306 315 324 GAA GAA ACT AAA CAA GAC ATC TTA GAC GTG CTA ATT CGG TGC TAC CTG TGT CAC Glu Glu Thr Lys Gin Asp Ile Leu Asp Val Leu Ile Arg Cys Tyr Leu Cys His 333 342 351 360 369 378 AAA CCG CTG TGT GAA GTA GAA AAG GTA AAA CAT ATA CTA ACC AAG GCG CGG TTC Lys Pro Leu Cys Glu Val Glu Lys Val Lys His Ile Leu Thr Lys Ala Arg Phe 387 396 405 414 423 432 ATA AAG CTA AAT TGT ACG TGG AAG GGT CGC TGC CTA CAC TGC TGG ACA ACA TGC Ile Lys Leu Asn Cys Thr Trp Lys Gly Arg Cys Leu His Cys Trp Thr Thr Cys 441 450 ._- 459 468 477 486 ATG GAA GAC ATG TTA CCC AAG CTT CAT GGA AGA CAT GTT ACC CTA AAG GAT ATT Met Glu Asp Met Leu Pro Lys Leu His Gly Arg His Val Thr Leu Lys Asp Ile 495 504 513 522 531 540 GTA TTA GAC CTG CAA CCT CCA GAC CCT GTA GGG TTA CAT TGC TAT GAG CAA TTA Val Leu Asp Leu Gin Pro Pro Asp Pro Val Gly Leu His Cys Tyr Glu Gin Leu 549 558 567 576 585 594 GTA GAC AGC TCA GAA GAT GAG GTG GAC GAA GTG GAC GGA CAA GAT TCA CAA CCT Val Asp Ser Ser Glu Asp Glu Val Asp Glu Val Asp Gly Gin Asp Ser Gin Pro 603 612 621 630 639 648 TTA AAA CAA CAT TTC CAA ATA GTG ACC TGT TGC TGT GGA TGT GAC AGC AAC GTT Leu Lys Gin His Phe Gin Ile Val Thr Cys Cys Cys Gly Cys Asp Ser Asn Val 657 666 675 684 693 702 CGA CTG GTT GTG CAG TGT ACA GAA ACA GAC ATC AGA GAA GTG CAA CAG CTT CTG Arg Leu Val Val Gin Cys Thr Glu Thr Asp Ile Arg Glu Val Gin Gin Leu Leu 711 720 729 738 745 756 TTG GGA ACA CTA AAC ATA GTG TGT CCC ATC TGC GCA CCG AAG ACC CCA TGG TCT Leu Gly Thr Leu Asn Ile Val Cys Pro Ile Cys Ala Pro Lys Thr Pro Trp Ser 765 774 783 792 801 810 AGA GAG CTC GGT ACC ACT AAT GGA GCA CCA AAC ATT GGG AAG TAT GTT ATG GCA Arg Glu Leu Gly Thr Thr Asn Gly Ala Pro Asn Ile Gly Lys Tyr Val Met Ala 819 828 837 846 855 864 GCA CAG TTA TAT GTT CTC CTG CAT CTG TAT CTA GCA CTA CAC AAG AAG TAT CCA Ala Gin Leu Tyr Val Leu Leu His Leu Tyr Leu Ala Leu His Lys Lys Tyr Pro 873 882 891 900 909 918 TTC CTG AAT CTA CTA CAT ACA CCC CCG CAC AGA CCT CCA CCC TTG TGT CCT CAA Phe Leu Asn Leu Leu His Thr Pro Pro His Arg Pro Pro Pro Leu Cys Pro Gin 927 936 945 954 963 972 GCA CCA AGG AAG ACG CAG TGC AAA CGC CGC CTA GGA AAC GAG CAC GAG GAG TCC Ala Pro Arg Lys Thr Gin Cys Lys Arg Arg Leu Gly Asn Glu His Glu Glu Ser 981 990 999 1008 1017 1026 AAC AGT CCC CTT GCA ACG CCT TGT GTG TGG CCC ACA TTG GAC CCG TGG ACA GTG Asn Ser Pro Leu Ala Thr Pro Cys Val Trp Pro Thr Leu Asp Pro Trp Thr Val 1035 1044 1053 1062 1071 1080 GAA ACC ACA ACC TCA TCA CTA ACA ATC ACG ACC AGC ACC AAA GAC GGA ACA ACA Glu Thr Thr Thr Ser Ser Leu Thr Ile Thr Thr Ser Thr Lys Asp Gly Thr Thr 1089 1098 1107 1116 1125 GTA ACA GTT CAG CTA CGC CTA AGA TCT CAT CAC CAT CAC CAT CAC TAA 3* Val Thr Val Gin Leu Arg Leu Arg Ser His His His His His His *** File : CSL673.DNA Range : 1 - 13 "" Mode : Normal Codon Table : Universal E6/E7/E5a E4 - SEQ ID Nos. 23 (DNA) and 24 (amino acid) 9 18 27 36 45 54 5' ATG GAA AGT GCA AAT GCC TCC ACG TCT GCA ACG ACC ATA GAC CAG TTG TGC AAG Met Glu Ser Ala Asn Ala Ser Thr Ser Ala Thr Thr Ile Asp Gin Leu Cys Lys 63 72 81 90 99 108 ACG TTT AAT CTA TCT ATG CAT ACG TTG CAA ATT AAT TGT GTG TTT TGC AAG AAT Thr Phe Asn Leu Ser Met His Thr Leu Gin Ile Asn Cys Val Phe Cys Lys Asn 117 126 135 144 153 162 GCA CTG ACC ACA GCA GAG ATT TAT TCA TAT GCA TAT AAA CAC CTA AAG GTC CTG Ala Leu Thr Thr Ala Glu Ile Tyr Ser Tyr Ala Tyr Lys His Leu Lys Val Leu 171 180 189 198 207 216 TTT CGA GGC GGC TAT CCA TAT GCA GCC TGC GCG TGC TGC CTA GAA TTT CAT GGA Phe Arg Gly Gly Tyr Pro Tyr Ala Ala Cys Ala Cys Cys Leu Glu Phe His Gly 225 234 243 252 261 270 AAA ATA AAC CAA TAT AGA CAC TTT GAT TAT GCT GGA TAT GCA ACA ACA GTT GAA Lys Ile Asn Gin Tyr Arg His Phe Asp Tyr Ala Gly Tyr Ala Thr Thr Val Glu 279 288 297 306 315 324 GAA GAA ACT AAA CAA GAC ATC TTA GAC GTG CTA ATT CGG TGC TAC CTG TGT CAC Glu Glu Thr Lys Gin Asp Ile Leu Asp Val Leu Ile Arg Cys Tyr Leu Cys His 333 342 351 360 369 378 AAA CCG CTG TGT GAA GTA GAA AAG GTA AAA CAT ATA CTA ACC AAG GCG CGG TTC Lys Pro Leu Cys Glu Val Glu Lys Val Lys His Ile Leu Thr Lys Ala Arg Phe 387 396 405 414 423 432 ATA AAG CTA AAT TGT ACG TGG AAG GGT CGC TGC CTA CAC TGC TGG ACA ACA TGC Ile Lys Leu Asn Cys Thr Trp Lys Gly Arg Cys Leu His Cys Trp Thr Thr Cys 441 450 459 468 477 486 ATG GAA GAC ATG TTA CCC AAG CTT CAT GGA AGA CAT GTT ACC CTA AAG GAT ATT Met Glu Asp Met Leu Pro Lys Leu His Gly Arg His Val Thr Leu Lys Asp Ile 495 504 513 522 531 540 GTA TTA GAC CTG CAA CCT CCA GAC CCT GTA GGG TTA CAT TGC TAT GAG CAA TTA Val Leu Asp Leu Gin Pro Pro Asp Pro Val Gly Leu His Cys Tyr Glu Gin Leu 549 558 567 576 585 594 GTA GAC AGC TCA GAA GAT GAG GTG GAC GAA GTG GAC GGA CAA GAT TCA CAA CCT Val Asp Ser Ser Glu Asp Glu Val Asp Glu Val Asp Gly Gin Asp Ser Gin Pro 603 612 621 630 639 648 TTA AAA CAA CAT TTC CAA ATA GTG ACC TGT TGC TGT GGA TGT GAC AGC AAC GTT Leu Lys Gin His Phe Gin Ile Val Thr Cys Cys Cys Gly Cys Asp Ser Asn Val 657 666 675 684 693 702 CGA CTG GTT GTG CAG TGT ACA GAA ACA GAC ATC AGA GAA GTG CAA CAG CTT CTG Arg Leu Val Val Gin Cys Thr Glu Thr Asp Ile Arg Glu Val Gin Gin Leu Leu 711 720 729 738 747 756 TTG GGA ACA CTA AAC ATA GTG TGT CCC ATC TGC GCA CCG AAG ACC CCA TGG GAA Leu Gly Thr Leu Asn Ile Val Cys Pro Ile Cys Ala Pro Lys Thr Pro Trp Glu 765 774 783 792 801 810 GTG GTG CCT GTA CAA ATA GCT GCA GGA ACA ACC AGC ACA TTC ATA CTG CCT GTT Val Val Pro Val Gin Ile Ala Ala Gly Thr Thr Ser Thr Phe Ile Leu Pro Val 819 828 837 846 855 864 ATA ATT GCA TTT GTT GTA TGT TTT GTT AGC ATC ATA CTT ATT GTA TGG ATA TCT Ile Ile Ala Phe Val Val Cys Phe Val Ser Ile Ile Leu Ile Val Trp Ile Ser 873 882 891 900 909 918 GAG TTT ATT GTG TAC ACA TCT GTG CTA GTA CTA ACA CTG CTT TTA TAT TTA CTA Glu Phe Ile Val Tyr Thr Ser Val Leu Val Leu Thr Leu Leu Leu Tyr Leu Leu 927 936 945 954 963 972 TTG TGG CTG CTA TTA ACA ACC CCC TTG CAA TTT TTC CTA CTA ACT CTA CTT GTG Leu Trp Leu Leu Leu Thr Thr Pro Leu Gin Phe Phe Leu Leu Thr Leu Leu Val 981 990 999 1008 1017 1026 TGT TAC TGT CCC GCA TTG TAT ATA CAC TAC TAT ATT GTT ACC ACA CAG CAA TCT Cys Tyr Cys Pro Ala Leu Tyr Ile His Tyr Tyr Ile Val Thr Thr Gin Gin Ser 1035 1044 1053 1062 1071 1080 AGA GAG CTC GGT ACC ACT AAT GGA GCA CCA AAC ATT GGG AAG TAT GTT ATG GCA Arg Glu Leu Gly Thr Thr Asn Gly Ala Pro Asn Ile Gly Lys Tyr Val Met Ala 1089 1098 1107 1116 1125 1134 GCA CAG TTA TAT GTT CTC CTG CAT CTG TAT CTA GCA CTA CAC AAG AAG TAT CCA Ala Gin Leu Tyr Val Leu Leu His Leu Tyr Leu Ala Leu His Lys Lys Tyr Pro 1143 1152 1161 1170 1179 1188 TTC CTG AAT CTA CTA CAT ACA CCC CCG CAC AGA CCT CCA CCC TTG TGT CCT CAA Phe Leu Asn Leu Leu His Thr Pro Pro His Arg Pro Pro Pro Leu Cys Pro Gin 1197 1206 1215 1224 1233 1242 GCA CCA AGG AAG ACG CAG TGC AAA CGC CGC CTA GGA AAC GAG CAC GAG GAG TCC Ala Pro Arg Lys Thr Gin Cys Lys Arg Arg Leu Gly Asn Glu His Glu Glu Ser 1251 1260 1269 1278 1287 1296 AAC AGT CCC CTT GCA ACG CCT TGT GTG TGG CCC ACA TTG GAC CCG TGG ACA GTG Asn Ser Pro Leu Ala Thr Pro Cys Val Trp Pro Thr Leu Asp Pro Trp Thr Val 1305 1314 1323 1332 1341 1350 GAA ACC ACA ACC TCA TCA CTA ACA ATC ACG ACC AGC ACC AAA GAC GGA ACA ACA Glu Thr Thr Thr Ser Ser Leu Thr Ile Thr Thr Ser Thr Lys Asp Gly Thr Thr 1359 1368 1377 1386 1395 GTA ACA GTT CAG CTA CGC CTA AGA TCT CAT CAC CAT CAC CAT CAC TAA 3' Val Thr Val Gin Leu Arg Leu Arg Ser His His His His His His *** Junction of El and E4 ORFs for CS 791 and CSL762 SEQ ID Nos. 25(DNA)and 26(amino acid) Modified Jfcnl Spel 5' GAG GAA GAT GGA AGC AAT AGC CAA GCG TTT AGA TGC GTG CCA GGA ACA GTT GTT AGA ACT TTA GGT ACC ACT AAT GGA GCA CCA AAC ATT GGG AAG TAT GTT ATG GCA 3* Glu Glu Asp Gly Ser Asn Ser Gin Ala Phe Arg Cys Val Pro Gly Thr Val Val Arg Thr Leu Gly Thr Thr Asn Gly Ala Pro Asn Ile Gly Lys Tyr Val Met Ala El E4 Junction of E5a and El for CSL762 SEQ ID Nos. 27 (DNA)and 28 (amino acid) I JCbal Sacl ro TI 5' TGT CCC GCA TTG TAT ATA CAC TAC TAT ATT GTT ACC ACA CAG CAA TCT AGA GAG CTC GCG GAC GAT TCA GGT ACA GAA AAT GAG GGG TCT GGG TGT ACA GGA 3' i Cys Pro Ala Leu Tyr lie His Tyr Tyr He Val Thr Thr Gin Gin Ser Arg Glu Leu Ala Asp Asp Ser Gly Thr Glu Asn Glu Gly Ser Gly Cys Thr Gly ' E5a El H Junction of E7 and El for CS 791 SEQ ID Nos. 29(DNA) and 30(amino acid) αol Xbal Sacl 5' TTG GGA ACA CTA AAC ATA GTG TGT CCC ATC TGC GCA CCG AAG ACC CCA TGG TCT AGA GAG CTC GCG GAC GAT TCA GGT ACA GAA AAT GAG GGG TCT GGG TGT ACA GGA 3' Leu Gly Thr Leu Asn lie Val Cys Pro Ile Cys Ala Pro Lys Thr Pro Trp Ser Arg Glu Leu Ala Asp Asp Ser Gly Thr Glu Asn Glu Gly Ser Gly Cys Thr Gly Example 4 - Preparation of antibodies to HPV6b early ORF protein products The following peptides corresponding to portions of the sequence of the relevant E proteins, were synthesised and conjugated to diphtheria toxoid: E6 dip. tox-C-QYRHFDYAQYATTVEEETKQDILD E7 MHGRHVTLKDIVLDLQPPD-C-dip. tox For the E6 peptide two rabbits (following pre-bleeding) were each inoculated with approximately 54 /g peptide/104/yg diphtheria toxoid in Freund's complete adjuvant followed at 3-weekly intervals by a similar dose of peptide conjugate in Freund's incomplete adjuvant. Bleeds were taken one week after the second dose and one week following the third dose. The same regime was used for the E7 peptide using 45μg peptide/103 μg diphtheria toxoid. Serum derived from the bleeds were tested for specific antibody in a solid phase EIA against biotin-conjugated peptide which had been bound to plates coated with strepavidin. Example 5 - Purification of polyprotein E6/E7/E4 The trimer polyprotein E6/E7/E4 was expressed in f. coli BL21 cells by induction of cells at OD 600 ~ 1 using 0.4mM IPTG. The cells were harvested by centrifugation (4,000g, 20 minutes), resuspended in 30mM Tris pH8.0, disrupted by sonication (MSE, amplitude 18//m, 4 x 30 seconds) and inclusion bodies pelleted by centrifugation (12,000g, 30 minutes). The pellet containing the trimer was solubilized in 8M Urea, 30mM Tris pHδ.O for 16 hours in the presence of protease inhibitors (Boehringer Cat. No. 1697498) and then centrifuged at 12,000g for 30 minutes and the supernatant collected. To this, Tris-(2-carboxyethyl)phosphine (TCEP) [Pierce] was added to 1.2mM final concentration. The supernatant was applied to Q-sepharose HP (Pharmacia) and the column washed with one column volume of 8M Urea, 1.2mM TCEP, 30 mM Tris pH8.0. Fractions were then eluted using a gradient containing 0 to 1M NaCl in 10 column volumes of the washing buffer. The fractions obtained were examined by Western blot from 4 to 20% SDS-PAGE probed with the anti-E4 antibody MWE4. Figure 1 1 shows a Western blot of material obtained from Q-sepharose. An immunoreactive band of ~ 41 kDa is evident in supernatant material from the urea solubilisation lane 3, and in fractions corresponding to 120 to 150 mM NaCl (lanes 8 and 9, arrow). Supernatant from the urea solublisation was also applied to a column containing Chelating Sepharose Fast Flow (Pharmacia) to take advantage of the C-terminal six histidine sequence. Relatively poor binding of the trimer to the Nickel column was observed under the conditions described. The trimer was eluted from the column using a 0 to 500 mM imidazole gradient. Example 6 In a further example of the present invention, a DNA sequence coding for a single polyprotein (Fig. 12) is formed by fusion of DNA fragments encoding HPV-6 early ORF proteins wherein the order of the ORFs is E2, E4, E5a, E5b, E6, E7 and El. The DNA sequences encoding the early ORF proteins are amplified individually by PCR using HPV-6 genomic DNA using the primers set out in Table 2. Table 2 The primers are synthesised to incorporate artificial restriction enzyme sites at the 5' and 3' termini of the amplification products. These restriction enzyme sites are used to facilitate the fusion of PCR products encoding the appropriate early ORF proteins in the desired order and in the correct translational frame. The restriction enzyme sites are also used to aid the cloning of the PCR products into the expression vector pTrcHisA. When cloned into this vector, the polyprotein construct is expressed as an N-terminal hexaHis fusion. The nucleotide sequence and deduced amino acid sequence of this fusion are shown below (SEQ ID Nos. 45 and 46, respectively). INFORMATION FOR HEXAHIS-POLYPROTEIN FUSION SEQUENCE: (I) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4770 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (lii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: HUMAN PAPILLOMAVIRUS TYPE 6 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..4761 (D) OTHER INFORMATIO :/codon_start= 1 /product= "HPV-6 Polyprotein" (IX) FEATURE: (A) NAME/KEY : πusc_RNA (B) LOCATION : 1. . 108 (D) OTHER INFORMATION: /functιon= "Tag used for protein purification" /product= "hexaHis leader sequence from pTrcHisA" (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 109..114 (D) OTHER INFORMATION: /label= Sacl (ix) FEATURE: (A) NAME/KEY: mRNA (B) LOCATION: 115..1218 (D) OTHER INFORMATION: /gene= "HPV-6 E2" (ix) FEATURE: (A) NAME/KEY: mιsc_feature (B) LOCATION: 1219..1224 (D) OTHER INFORMATION: /label= Sail (ix) FEATURE: (A) NAME/KEY: mRNA (B) LOCATION: 1225..1551 (D) OTHER INFORMATION: /gene= "HPV-6 E4" (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 1552..1557 (D) OTHER INFORMATION: /label= Bglll (ix) FEATURE: (A) NAME/KEY: mRNA (B) LOCATION: 1558..1830 (D) OTHER INFORMATION: /gene= "HPV-6 E5a" (ix) FEATURE: (A) NAME/KEY: mιsc_feature (B) LOCATION: 1831..1836 (D) OTHER INFORMATION: /label= Bfrl (ix) FEATURE: (A) NAME/KEY: mRNA (B) LOCATION: 1837..2052 (D) OTHER INFORMATION: /gene= "HPV-6 E5b" (ix) FEATURE : (A) NAME/KEY: πasc_ eature (B) LOCATION:2053..2058 (D) OTHER INFORMATION: /label= SacII (XX) FEATURE: (A) NAME/KEY: mRNA (B) LOCATION:2059..2508 (D) OTHER INFORMATION: /gene= "HPV-6 E6" (ix) FEATURE: (A) NAME/KEY: misc_ eature (B) LOCATION:2509..2514 (D) OTHER INFORMATION: /label= Nhel (ix) FEATURE: (A) NAME/KEY: mRNA (B) LOCATION: 2515..2808 (D) OTHER INFORMATION: /gene= "HPV-6 E7" (ix) FEATURE: (A) NAME/KEY: mis _feature (B) LOCATION: 2809..2814 (D) OTHER INFORMATION: /label= Pvul (IX) FEATURE: (A) NAME/KEY: mRNA (B) LOCATION:2815..4764 (D) OTHER INFORMATION: /gene= "HPV-6 El" (IX) FEATURE: (A) NAME/KEY: mιsc_feature (B) LOCATION: 4765..4770 (D) OTHER INFORMATION: /label= Kpnl ATG GGG GGT TCT CAT CAT CAT CAT CAT CAT GGT ATG GCT AGC ATG ACT 48 Met Gly Gly Ser His His His H s His His Gly Met Ala Ser Met Thr 1 5 10 15 GGT GGA CAG CAA ATG GGT CGG GAT CTG TAC GAC GAT GAC GAT AAG GAT 96 Gly Gly Gin Gin Met Gly Arg Asp Leu Tyr Asp Asp Asp Asp Lys Asp 20 25 30 CGA TGG GGA TCC GAG CTC ATG GAA GCA ATA GCC AAG CGT TTA GAT GCG 144 Arg Trp Gly Ser Glu Leu Met Glu Ala Ile Ala Lys Arg Leu Asp Ala 35 40 45 TGC CAG GAA CAG TTG TTA GAA CTT TAT GAA GAA AAC AGT ACT GAC CTA 192 Cys Gin Glu Gin Leu Leu Glu Leu Tyr Glu Glu Asn Ser Thr Asp Leu 50 55 60 CAC AAA CAT GTA TTG CAT TGG AAA TGC ATG AGA CAT GAA AGT GTA TTA 240 His Lys His Val Leu His Trp Lys Cys Met Arg His Glu Ser Val Leu 65 70 75 80 TTA TAT AAA GCA AAA CAA ATG GGC CTA AGC CAC ATA GGA ATG CAA GTA 288 Leu Tyr Lys Ala Lys Gin Met Gly Leu Ser His Ile Gly Met Gin Val 85 90 95 GTG CCA CCA TTA AAG GTG TCC GAA GCA AAA GGA CAT AAT GCC ATT GAA 336 Val Pro Pro Leu Lys Val Ser Glu Ala Lys Gly His Asn Ala Ile Glu 100 105 110 ATG CAA ATG CAT TTA GAA TCA TTA TTA AGG ACT GAG TAT AGT ATG GAA 384 Met Gin Met His Leu Glu Ser Leu Leu Arg Thr Glu Tyr Ser Met Glu 115 120 125 CCG TGG ACA TTA CAA GAA ACA AGT TAT GAA ATG TGG CAA ACA CCA CCT 432 Pro Trp Thr Leu Gin Glu Thr Ser Tyr Glu Met Trp Gin Thr Pro Pro "* 130 135 140 AAA CGC TGT TTT AAA AAA CGG GGC AAA ACT GTA GAA GTT AAA TTT GAT 480 Lys Arg Cys Phe Lys Lys Arg Gly Lys Thr Val Glu Val Lys Phe Asp A 96/00473 - 36 - 145 150 155 160 GGC TGT GCA AAC AAT ACA ATG GAT TAT GTG GTA TGG ACA GAT GTG TAT 528 Gly Cys Ala Asn Asn Thr Met Asp Tyr Val Val Trp Thr Asp Val Tyr 165 170 175 GTG CAG GAC AAT GAC ACC TGG GTA AAG GTG CAT AGT ATG GTA GAT GCT 576 Val Gin Asp Asn Asp Thr Trp Val Lys Val His Ser Met Val Asp Ala 180 185 190 AAG GGT ATA TAT TAC ACA TGT GGA CAA TTT AAA ACA TAT TAT GTA AAC 624 Lys Gly Ile Tyr Tyr Thr Cys Gly Gin Phe Lys Thr Tyr Tyr Val Asn 195 200 205 TTT GTA AAA GAG GCA GAA AAG TAT GGG 672 Phe Val Lys Glu Ala Glu Lys Tyr Gly 210 215 TGT TAT GGC AGC ACA GTT ATA TGT TCT 720 Cys Tyr Gly Ser Thr Val Ile Cys Ser 225 230 ACA CAA GAA GTA TCC ATT CCT GAA TCT 768 Thr Gin Glu Val Ser Ile Pro Glu Ser 245 ACC TCC ACC CTT GTG TCC TCA AGC ACC 816 Thr Sex Thr Leu Val Ser Ser Ser Thr 260 265 CCG CCT AGG AAA CGA GCA CGA GGA GTC 864 Pro Pro Arg Lys Arg Ala Arg Gly Val 275 280 TTG TGT GTG GCC CAC ATT GGA CCC GTG 912 Leu Cys Val Ala His Ile Gly Pro Val 290 295 ATC ACT AAC AAT CAC GAC CAG CAC CAA 960 Ile Thr Asn Asn His Asp Gin His Gin 305 310 TCA GCT ACG CCT ATA GTG CAA TTT CAA 1008 Ser Ala Thr Pro Ile Val Gin Phe Gin 325 TGT TTT AGA TAT AGG CTA AAT GAC AGA 1056 Cys Phe Arg Tyr Arg Leu Asn Asp Arg 340 345 ATA TCA TCA ACG TGG CAC TGG GCC TCC 1104 Ile Ser Ser Thr Trp His Trp Ala Ser 355 360 GCC ATT GTA ACT GTA ACA TAT GAT AGT 1152 Ala Ile Val Thr Val Thr Tyr Asp Ser 370 375 TTA GAT GTT GTA AAA ATA CCC CCT ACC 1200 Leu Asp Val Val Lys Ile Pro Pro Thr 385 390 ATG TCA CTG CAC CTA TTG GTC GAC ATG 1248 Met Ser Leu His Leu Leu Val Asp Met 405 TAT GTT ATG GCA GCA CAG TTA TAT GTT 1296 Tyr Val Met Ala Ala Gin Leu Tyr Val 420 425 CTA CAC AAG AAG TAT CCA TTC CTG AAT 1344 Leu His Lys Lys Tyr Pro Phe Leu Asn 435 440 - 37 - AGA CCT CCA CCC TTG TGT CCT CAA GCA CCA AGG AAG ACG CAG TGC AAA 1392 Arg Pro Pro Pro Leu Cys Pro Gin Ala Pro Axg Lys Thr Gin Cys Lys 450 455 460 CGC CGC CTA GGA AAC GAG CAC GAG GAG TCC AAC AGT CCC CTT GCA ACG 1440 Arg Arg Leu Gly Asn Glu His Glu Glu Ser Asn Ser Pro Leu Ala Thr 465 470 475 480 CCT TGT GTG TGG CCC ACA TTG GAC CCG TGG ACA GTG GAA ACC ACA ACC 1488 Pro Cys Val Trp Pro Thr Leu Asp Pro Trp Thr Val Glu Thr Thr Thr 485 490 495 TCA TCA CTA ACA ATC ACG ACC AGC ACC AAA GAC GGA ACA ACA GTA ACA 1536 Ser Se∑ Leu Thr Ile Thr Thr Ser Thr Lys Asp Gly Thr Thr Val Thr 500 505 510 GTT CAG CTA CGC CTA AGA TCT ATG GAA GTG GTG CCT GTA CAA ATA GCT 1584 Val Gin Leu Arg Leu Arg Ser Met Glu Val Val Pro Val Gin Ile Ala S15 520 525 GCA GGA ACA ACC AGC ACA TTC ATA CTG CCT GTT ATA ATT GCA TTT GTT 1632 Ala Gly Thr Thr Ser Thr Phe Ile Leu Pro Val lie Ile Ala Phe Val 530 535 540 GTA TGT TTT GTT AGC ATC ATA CTT ATT GTA TGG ATA TCT GAG TTT ATT 1680 Val Cys Phe Val Ser Ile Ile Leu Ile Val Trp Ile Ser Glu Phe Ile 545 550 555 560 GTG TAC ACA TCT GTG CTA GTA CTA ACA CTG CTT TTA TAT TTA CTA TTG 1728 Val Tyr Thr Ser Val Leu Val Leu Thr Leu Leu Leu Tyr Leu Leu Leu 565 570 575 TGG CTG CTA TTA ACA ACC CCC TTG CAA TTT TTC CTA CTA ACT CTA CTT 1776 Trp Leu Leu Leu Thr Thr Pro Leu Gin Phe Phe Leu Leu Thr Leu Leu 580 585 590 GTG TGT TAG.TGT CCC GCA TTG TAT ATA CAC TAC TAT ATT GTT ACC ACA 1824 Val Cys Tyr Cys Pro Ala Leu Tyr Ile His Tyr Tyr lie Val Thr Thr 595 600 605 CAG CAA CTT AAG ATG ATG CTA ACA TGT CAA TTT AAT GAT GGA GAT ACC 1872 Gin Gin Leu Lys Met Met Leu Thr Cys Gin Phe Asn Asp Gly Asp Thr 610 615 620 TGG CTG GGT TTG TGG TTG TTA TGT GCC TTT ATT GTA GGG ATG TTG GGG 1920 Trp Leu Gly Leu Trp Leu Leu Cys Ala Phe Ile Val Gly Met Leu Gly 625 630 635 640 TTA TTA TTG ATG CAC TAT AGA GCT GTA CAA GGG GAT AAA CAC ACC AAA 1968 Leu Leu Leu Met His Tyr Arg Ala Val Gin Gly Asp Lys His Thr Lys 645 650 655 TGT AAG AAG TGT AAC AAA CAC AAC TGT AAT GAT GAT TAT GTA ACT ATG 2016 Cys Lys Lys Cys Asn Lys His Asn Cys Asn Asp Asp Tyr Val Thr Met 660 665 670 CAT TAT ACT ACT GAT GGT GAT TAT ATA TAT ATG AAT CCG CGG ATG GAA 2064 His Tyr Thr Thr Asp Gly Asp Tyr Ile Tyr Met Asn Pro Arg Met Glu 675 680 685 AGT GCA AAT GCC TCC ACG TCT GCA ACG ACC ATA GAC CAG TTG TGC AAG 2112 Ser Ala Asn Ala Ser Thr Ser Ala Thr Thr Ile Asp Gin Leu Cys Lys 690 695 700 ACG TTT AAT CTA TCT ATG CAT ACG TTG CAA ATT AAT TGT GTG TTT TGC 2160 Thr Phe Asn Leu Ser Met His Thr Leu Gin Ile Asn Cys Val Phe Cys 705 710 715 720 AAG AAT GCA CTG ACC ACA GCA GAG ATT TAT TCA TAT GCA TAT AAA CAC 2208 Lys Asn Ala Leu Thr Thr Ala Glu Ile Tyr Ser Tyr Ala Tyr Lys His 725 730 735 CTA AAG GTC CTG TTT CGA GGC GGC TAT CCA TAT GCA GCC TGC GCG TGC 2256 Leu Lys Val Leu Phe Arg Gly Gly Tyr Pro Tyr Ala Ala Cys Ala Cys 6/00473 - 38 - 740 745 750 TGC CTA GAA TTT CAT GGA AAA ATA AAC CAA TAT AGA CAC TTT GAT TAT 2304 Cys Leu Glu Phe His Gly Lys Ile Asn Gin Tyr Arg His Phe Asp Tyr 755 760 765 GCT GGA TAT GCA ACA ACA GTT GAA GAA GAA ACT AAA CAA GAC ATC TTA 2352 Ala Gly Tyr Ala Thr Thr Val Glu Glu Glu Thr Lys Gin Asp Ile Leu 770 775 780 GAC GTG CTA ATT CGG TGC TAC CTG TGT CAC AAA CCG CTG TGT GAA GTA 2400 Asp Val Leu Ile Arg Cys Tyr Leu Cys His Lys Pro Leu Cys Glu Val 785 790 795 800 GAA AAG GTA AAA CAT ATA CTA ACC AAG GCG CGG TTC ATA AAG CTA AAT 2448 Glu Lys Val Lys His Ile Leu Thr Lys Ala Arg Phe Ile Lys Leu Asn 805 810 815 TGT ACG TGG AAG GGT CGC TGC CTA CAC TGC TGG ACA ACA TGC ATG GAA 2496 Cys Thr Trp Lys Gly Arg Cys Leu His Cys Trp Thr Thr Cys Met Glu 820 825 830 GAC ATG TTA CCC GCT AGC ATG CAT GGA AGA CAT GTT ACC CTA AAG GAT 2544 Asp Met Leu Pro Ala Ser Met His Gly Arg His Val Thr Leu Lys Asp 835 840 845 ATT GTA TTA GAC CTG CAA CCT CCA GAC CCT GTA GGG TTA CAT TGC TAT 2592 Ile Val Leu Asp Leu Gin Pro Pro Asp Pro Val Gly Leu His Cys Tyr 850 855 860 GAG CAA TTA GTA GAC AGC TCA GAA GAT GAG GTG GAC GAA GTG GAC GGA 2640 Glu Gin Leu Val Asp Ser Ser Glu Asp Glu Val Asp Glu Val Asp Gly 865 870 875 880 CAA GAT TCA CAA CCT TTA AAA CAA CAT TTC CAA ATA GTG ACC TGT TGC 2688 Gin Asp Ser Gin Pro Leu Lys Gin His Phe Gin Ile Val Thr Cys Cys 885 890 895 TGT GGA TGT GAC AGC AAC GTT CGA CTG GTT GTG CAG TGT ACA GAA ACA 2736 Cys Gly Cys Asp Ser Asn Val Arg Leu Val Val Gin Cys Thr Glu Thr 900 905 910 GAC ATC AGA GAA GTG CAA CAG CTT CTG TTG GGA ACA CTA AAC ATA GTG 2784 Asp Ile Arg Glu Val Gin Gin Leu Leu Leu Gly Thr Leu Asn Ile Val 915 920 925 TGT CCC ATC TGC GCA CCG AAG ACC CGA TCG ATG GCG GAC GAT TCA GGT 2832 Cys Pro Ile Cys Ala Pro Lys Thr Arg Ser Met Ala Asp Asp Ser Gly 930 935 940 ACA GAA AAT GAG GGG TCT GGG TGT ACA GGA TGG TTT ATG GTA GAA GCT 2880 Thr Glu Asn Glu Gly Ser Gly Cys Thr Gly Trp Phe Met Val Glu Ala 945 950 955 960 ATA GTG CAA CAC CCA ACA GGT ACA CAA ATA TCA GAC GAT GAG GAT GAG 2928 Ile Val Gin His Pro Thr Gly Thr Gin Ile Ser Asp Asp Glu Asp Glu 965 970 975 GAG GTG GAG GAC AGT GGG TAT GAC ATG GTG GAC TTT ATT GAT GAC AGC 2976 Glu Val Glu Asp Ser Gly Tyr Asp Met Val Asp Phe Ile Asp Asp Ser 980 985 990 AAT ATT ACA CAC AAT TCA CTG GAA GCA CAG GCA TTG TTT AAC AGG CAG 3024 Asn Ile Thr His Asn Ser Leu Glu Ala Gin Ala Leu Phe Asn Arg Gin 995 1000 1005 GAG GCG GAC ACC CAT TAT GCG ACT GTG CAG GAC CTA AAA CGA AAG TAT 3072 Glu Ala Asp Thr His Tyr Ala Thr Val Gin Asp Leu Lys Arg Lys Tyr 1010 1015 1020 TTA GGT AGT CCA TAT GTT AGT CCT ATA AAC ACT ATA GCC GAG GCA GTG 3120 Leu Gly Ser Pro Tyr Val Ser Pro Ile Asn Thr Ile Ala Glu Ala Val 1025 1030 1035 1040 - 39 GAA AGT GAA ATA AGT CCA CGA TTG GAC GCC ATT AAA CTT ACA AGA CAG 3168 Glu Ser Glu Ile Ser Pro Arg Leu Asp Ala Ile Lys Leu Thr Arg Gin 1045 1050 1055 CCA AAA AAG GTA AAG CGA CGG CTG TTT CAA ACC AGG GAA CTA ACG GAC 3216 Pro Lys Lys Val Lys Arg Arg Leu Phe Gin Thr Arg Glu Leu Thr Asp 1060 1065 1070 AGT GGA TAT GGC TAT TCT GAA GTG GAA GCT GGA ACG GGA ACG CAG GTA 3264 Ser Gly Tyr Gly Tyr Ser Glu Val Glu Ala Gly Thr Gly Thr Gin Val 1075 1080 1085 GAG AAA CAT GGC GTA CCG GAA AAT GGG GGA GAT GGT CAG GAA AAG GAC 3312 Glu Lys His Gly Val Pro Glu Asn Gly Gly Asp Gly Gin Glu Lys Asp 1090 1095 1100 ACA GGA AGG GAC ATA GAG GGG GAG GAA CAT ACA GAG GCG GAA GCG CCC 3360 Thr Gly Arg Asp Ile Glu Gly Glu Glu His Thr Glu Ala Glu Ala Pro 1105 1110 1115 1120 ACA AAC AGT GTA CGG GAG CAT GCA GGC ACA GCA GGA ATA TTG GAA TTG 3408 Thr Asn Ser Val Arg Glu His Ala Gly Thr Ala Gly Ile Leu Glu Leu 1125 1130 1135 TTA AAA TGT AAA GAT TTA CGG GCA GCA TTA CTT GGT AAG TTT AAA GAA 3456 Leu Lys Cys Lys Asp Leu Arg Ala Ala Leu Leu Gly Lys Phe Lys Glu 1140 1145 1150 TGC TTT GGG CTG TCT TTT ATA GAT TTA ATT AGG CCA TTT AAA AGT GAT 3504 Cys Phe Gly Leu Ser Phe Ile Asp Leu Ile A g Pro Phe Lys Ser Asp 1155 1160 1165 AAA ACA ACA TGT TTA GAT TGG GTG GTA GCA GGG TTT GGT ATA CAT CAT 3552 Lys Thr Thr Cys Leu Asp Trp Val Val Ala Gly Phe Gly Ile His His 1170 1175 1180 AGC ATA TCA GAG GCA TTT CAA AAA TTA ATT GAG CCA TTA AGT TTA TAT 3600 Ser Ile Ser Glu Ala Phe Gin Lys Leu lie Glu Pro Leu Ser Leu Tyr 1185 1190 1195 1200 GCA CAT ATA CAA TGG CTA ACA AAT GCA TGG GGA ATG GTA TTG TTA GTA 3648 Ala His Ile Gin Trp Leu Thr Asn Ala Trp Gly Met Val Leu Leu Val 1205 1210 1215 TTA TTA AGA TTT AAA GTA AAT AAA AGT AGA AGT ACC GTT GCA CGT ACA 3696 Leu Leu Arg Phe Lys Val Asn Lys Ser Arg Ser Thr Val Ala Arg Thr 1220 1225 1230 CTT GCA ACG CTA TTA AAT ATA CCT GAA AAC CAA ATG TTA ATA GAG CCA 3744 Leu Ala Thr Leu Leu Asn Ile Pro Glu Asn Gin Met Leu Ile Glu Pro 1235 1240 1245 CCA AAA ATA CAA AGT GGT GTT GCA GCC CTG TAT TGG TTT CGT ACA GGT 3792 Pro Lys Ile Gin Ser Gly Val Ala Ala Leu Tyr Trp Phe Arg Thr Gly 1250 1255 1260 ATA TCA AAT GCC AGT ACA GTT ATA GGG GAA GCA CCA GAA TGG ATA ACA 3840 Ile Ser Asn Ala Ser Thr Val Ile Gly Glu Ala Pro Glu Trp Ile Thr 1265 1270 1275 1280 CGC CAA ACA GTT ATT GAA CAC GGG TTG GCA GAC AGT CAG TTT AAA TTA 3888 Arg Gin Thr Val Ile Glu His Gly Leu Ala Asp Ser Gin Phe Lys Leu 1285 1290 1295 ACA GAA ATG GTG CAG TGG GCG TAT GAT AAT GAC ATA TGC GAG GAG AGT 3936 Thr Glu Met Val Gin Trp Ala Tyr Asp Asn Asp Ile Cys Glu Glu Ser 1300 1305 1310 GAA ATT GCA TTT GAA TAT GCA CAA AGG GGA GAT TTT GAT TCT AAT GCA 3984_ Glu Ile Ala Phe Glu Tyr Ala Gin Arg Gl.y Asp Phe Asp Ser Asn Ala 1315 1320 1325 CGA GCA TTT TTA AAT AGC AAT ATG CAG GCA AAA TAT GTG AAA GAT TGT 4032 Arg Ala Phe Leu Asn Ser Asn Met Gin Ala Lys Tyr Val Lys Asp Cys - 40 - 1330 1335 1340 GCA ACT ATG TGT AGA CAT TAT AAA CAT GCA GAA ATG AGG AAG ATG TCT 4080 Ala Thr Met Cys Arg His Tyr Lys His Ala Glu Met Arg Lys Met Ser 1345 1350 1355 1360 ATA AAA CAA TGG ATA AAA CAT AGG GGT TCT AAA ATA GAA GGC ACA GGA 4128 Ile Lys Gin Trp Ile Lys His Arg Gly Ser Lys Ile Glu Gly Thr Gly 1365 1370 1375 AAT TGG AAA CCA ATT GTA CAA TTC CTA CGA CAT CAA AAT ATA GAA TTC 4176 Asn Trp Lys Pro Ile Val Gin Phe Leu Arg His Gin Asn Ile Glu Phe 1380 1385 1390 ATT CCT TTT TTA ACT AAA TTT AAA TTA TGG CTG CAC GGT ACG CCA AAA 422 Ile Pro Phe Leu Thr Lys Phe Lys Leu Trp Leu His Gly Thr Pro Lys 1395 1400 1405 AAA AAC TGC ATA GCC ATA GTA GGC CCT CCA GAT ACT GGG AAA TCG TAC 4272 Lys Asn Cys Ile Ala Ile Val Gly Pro Pro Asp Thr Gly Lys Ser Tyr 1410 1415 1420 TTT TGT ATG AGT TTA ATA AGC TTT CTA GGA GGT ACA GTT ATT AGT CAT 4320 Phe Cys Met Ser Leu Ile Ser Phe Leu Gly Gly Thr Val Ile Ser His 1425 1430 1435 1440 GTA AAT TCC AGC AGC CAT TTT TGG TTG CAA CCG TTA GTA GAT GCT AAG 4368 Val Asn Ser Ser Ser His Phe Trp Leu Gin Pro Leu Val Asp Ala Lys 1445 1450 1455 GTA GCA TTG TTA GAT GAT GCA ACA CAG CCA TGT TGG ATA TAT ATG GAT 4416 Val Ala Leu Leu Asp Asp Ala Thr Gin Pro Cys Trp Ile Tyr Met Asp 1460 1465 1470 ACA TAT ATG AGA AAT TTG TTA GAT GGT AAT CCT ATG AGT ATT GAC AGA 464 Thr Tyr Met Arg Asn Leu Leu Asp Gly Asn Pro Met Ser Ile Asp Arg 1475 1480 1485 AAG CAT AAA GCA TTG ACA TTA ATT AAA TGT CCA CCT CTG CTA GTA ACG 4512 Lys His Lys Ala Leu Thr Leu Ile Lys Cys Pro Pro Leu Leu Val Thr 1490 1495 1500 TCC AAC ATA GAT ATT ACT AAA GAA GAT AAA TAT AAG TAT TTA CAT ACT 4560 Ser Asn Ile Asp Ile Thr Lys Glu Asp Lys Tyr Lys Tyr Leu His Thr 1505 1510 1515 1520 AGA GTA ACA ACA TTT ACA TTT CCA AAT CCA TTC CCT TTT GAC AGA AAT 4608 Arg Val Thr Thr Phe Thr Phe Pro Asn Pro Phe Pro Phe Asp Arg Asn 1525 1530 1535 GGG AAT GCA GTG TAT GAA CTG TCA AAT ACA AAC TGG AAA TGT TTT TTT 4656 Gly Asn Ala Val Tyr Glu Leu Ser Asn Thr Asn Trp Lys Cys Phe Phe 1540 1545 1550 GAA AGA CTG TCG TCA AGC CTA GAC ATT CAG GAT TCT GAG GAC GAG GAA 4704 Glu Arg Leu Ser Ser Ser Leu Asp Ile Gin Asp Ser Glu Asp Glu Glu 1555 1560 1565 GAT GGA AGC AAT AGC CAA GCG TTT AGA TGC GTG CCA GGA ACA GTT GTT 4752 Asp Gly Ser Asn Ser Gin Ala Phe Arg Cys Val Pro Gly Thr Val Val 1570 1575 1580 AGA ACT TTA TGAGGTACC 4770 Arg Thr Leu 1585

Claims: CLAIMS: 1. A polyprotein construct comprising at least two amino acid sequences fused directly or indirectly together, each of said sequences being the sequence of an early ORF protein of papillomavirus (PV) or an immunogenic variant or fragment thereof, and at least one of said sequences being other than the E6 or E7 protein sequence or an immunogenic variant or fragment thereof. 2. A polyprotein construct according to claim 1, wherein said sequences are sequences of early ORF proteins of human PV, or immunogenic variants or fragments thereof. 3. A polyprotein construct according to claim 2, wherein said early ORF proteins are selected from the group consisting of the El, E2, E3, E4, E5 (E5a, E5b), E6, E7 and E8 proteins of PV. 4. A polyprotein construct according to any of claims 1 to 3, selected from the group consisting of: (m) E2/E4/E5a/E5b/E6/E7/E1 (n) E2/E3/E4/E5/E8/E6/E7/E 1. 5. A polyprotein construct according to claim 1, further comprising one or more linker sequences between and/or before and/or after said amino acid sequences. 6. A polyprotein construct according to claim 5, wherein said linker sequence(s) comprise from 1 to 5 amino acid residues. 7. A polyprotein construct according to claim 1, further comprising a tag protein or peptide moiety fused or otherwise coupled thereto. 8. A polyprotein construct according to claim 7, wherein said tag moiety is selected from the group consisting of (his) 6 , glutathione-S-transferase (GST) and FLAG. 9. A polyprotein construct according to claim 1, further comprising an adjuvant moiety fused or otherwise coupled thereto. 10. A polyprotein construct according to claim 9, wherein said adjuvant moiety is selected from diphtheria toxin, cholera toxin and E. coli heat labile toxin (LO and non-toxic derivatives thereof such as the holotoxoid or B sub-unit of cholera toxin or LT. 11. A polyprotein construct according to claim 1, further comprising a lipid binding region. 12. A polyprotein construct according to claim 1 1, wherein said lipid binding region is an influenza haemagglutinin tail. 13. A composition for eliciting a humoral and/or cellular immune response against papillomavirus in a host animal, said composition comprising an immunologically effective amount of a polyprotein construct according to any of claims 1 to 12, together with a pharmaceutically acceptable carrier and/or diluent. 14. A vaccine composition according to claim 13, further comprising an adjuvant. 15. A method for eliciting a humoral and/or cellular response against papillomavirus in a host animal, which method comprises administering to the host animal an immunologically effective amount of a polyprotein construct according to any of claims 1 to 12. 16. A method according to claim 15, wherein said polyprotein construct is administered in a composition together with a pharmaceutically acceptable carrier and/or diluent. 17. A method according to claim 16, wherein said composition further comprises an adjuvant. 18. A method according to any of claims 15 to 17, wherein said host animal is a human. 19. Use of a polyprotein construct according to any of claims 1 to 12, in eliciting an immune response against papillomavirus in a host animal. 20. A nucleic acid molecule which encodes a polyprotein construct according to any of claims 1 to 12. 21. A recombinant DNA molecule comprising an expression control sequence operatively linked to a nucleic acid molecule according to claim 20. 22. A recombinant DNA molecule according to claim 21, wherein said expression control sequence comprises promoter and initiator sequences, the sequence of nucleotides encoding the polyprotein construct being located in a single translational frame 3' to the promoter and initiator sequences, and a termination sequence located 3' to said sequence of nucleotides. 23. A recombinant DNA cloning vehicle or vector comprising a recombinant DNA molecule according to claim 21 or claim 22. 24. A recombinant DNA cloning vehicle or vector according to claim 23, wherein said vector is a plasmid. 25. A host cell transfected or transformed with a recombinant DNA molecule according to claim 21 or claim 22, or a recombinant DNA cloning vehicle or vector according to claim 23 or claim 24. 26. A host cell according to claim 25, wherein said host cell is f. coli. 27. A recombinant polyprotein construct prepared by expression in a host cell according to claim 25 or claim 26. 28. A composition comprising a nucleic acid molecule according to claim 20, together with a pharmaceutically acceptable carrier and/or diluent. 29. A method for eliciting an immune response against PV in a host animal, which method comprises administering to the host animal an immunologically effective amount of a nucleic acid molecule according to claim 20. 30. Use of a nucleic acid molecule according to claim 20 in eliciting an immune response against PV in a host animal.

Inventors: COX JOHN COOPER, EDWARDS STIRLING JOHN, FRAZER IAN, MARGETTS MARY BRIGID, MCMILLAN NIGEL ALAN JOHN, MOLONEY MARGARET BRIDGET HOLLA, WEBB ELIZABETH ANN, WILLIAMS MARK PHILIP, COX, JOHN, COOPER, EDWARDS, STIRLING, JOHN, FRAZER, IAN, MARGETTS, MARY, BRIGID, MCMILLAN, NIGEL, ALAN, JOHN, MOLONEY, MARGARET, BRIDGET, HOLLAND, WEBB, ELIZABETH, ANN, WILLIAMS, MARK, PHILIP
Applicants: COX JOHN COOPER, CSL LTD, EDWARDS STIRLING JOHN, FRAZER IAN, MARGETTS MARY BRIGID, MCMILLAN NIGEL ALAN JOHN, MOLONEY MARGARET BRIDGET HOLLA, UNIV QUEENSLAND, WEBB ELIZABETH ANN, WILLIAMS MARK PHILIP, COX, JOHN, COOPER, CSL LIMITED, EDWARDS, STIRLING, JOHN, FRAZER, IAN, MARGETTS, MARY, BRIGID, MCMILLAN, NIGEL, ALAN, JOHN, MOLONEY, MARGARET, BRIDGET, HOLLAND, THE UNIVERSITY OF QUEENSLAND, WEBB, ELIZABETH, ANN, WILLIAMS, MARK, PHILIP
Application year: 1996
Main classification: C07K14
IPC codes: A61K31, A61K39, A61P31, C07K14, C12N1, C12N15, C12P21, C12R1